NAD+ and Its Precursors: What the Human Trials Report
By Benn Bluestein-Veyra, M.Sc. Organic Chemistry · Updated 9 November 2026
ExaVeyra Sciences is a Miami-based B2B supplier of exosomes for topical aesthetic use to licensed clinics, and it works with a 503A compounding pharmacy that prepares formulations for licensed prescribers against individual prescriptions.
| Question | Answer |
|---|---|
| What this page covers | NAD+ injection evidence: what the human trials of nicotinamide riboside, NMN and intravenous NAD+ report, plus the FDA record on NMN and compounded NAD+. |
| Who can order | Licensed clinics and practitioners whose active professional license and NPI ExaVeyra has verified. Exosome orders also require a signed professional-use acknowledgment. |
| What ships, and how | Compounded formulations are prepared and dispensed by our 503A pharmacy partner against a patient-specific prescription from the licensed prescriber and ship from the pharmacy. The pharmacy dispenses any controlled substance under its own DEA registration. |
The human evidence for NAD+ comes almost entirely from oral precursor trials. A 2026 PRISMA-guided systematic review of 113 studies, 33 of them in humans, reported that oral nicotinamide riboside and nicotinamide mononucleotide "consistently demonstrated biochemical target engagement" and "were generally well tolerated over weeks to months", while effects on functional, metabolic and vascular outcomes "were heterogeneous and often null or endpoint-specific".[1] The same review found that "No eligible outcomes trials evaluated intravenous or intramuscular NAD⁺ itself for anti-aging or wellness indications".[1] The one controlled intravenous pilot infused NAD+ into eight men over six hours and detected no change in plasma NAD+ or its metabolites until after the second hour.[2]
NAD+ is a redox coenzyme and a substrate for sirtuins, PARPs and CD38
Nicotinamide adenine dinucleotide cycles between an oxidized form, NAD+, and a reduced form, NADH, carrying electrons through glycolysis, the citric acid cycle and the respiratory chain.[3] The NIH Office of Dietary Supplements states that "More than 400 enzymes require NAD to catalyze reactions in the body, which is more than for any other vitamin-derived coenzyme", and that NAD is also converted to NADP, which "enables anabolic reactions, such as the synthesis of cholesterol and fatty acids".[4] A second set of enzymes consumes NAD+ rather than recycling it: the 2021 review by Covarrubias and colleagues describes NAD+ as "an essential cofactor for non-redox NAD+-dependent enzymes, including sirtuins, CD38 and poly(ADP-ribose) polymerases", records that "ageing is accompanied by a gradual decline in tissue and cellular NAD+ levels in multiple model organisms, including rodents and humans", and adds that it remains to be learned "how to effectively restore NAD+ levels during ageing, whether doing so is safe and whether NAD+ repletion will have beneficial effects in ageing humans".[3]
The CD38 finding is preclinical. Camacho-Pereira and colleagues reported in 2016 that CD38 activity increases with aging in mice, that CD38 "is required for the age-related NAD decline and mitochondrial dysfunction", and that it is "the main enzyme involved in the degradation of the NAD precursor nicotinamide mononucleotide (NMN) in vivo".[5] The precursors sit upstream: niacin is "the generic name for nicotinic acid (pyridine-3-carboxylic acid), nicotinamide (niacinamide or pyridine-3-carboxamide), and related derivatives, such as nicotinamide riboside", and "When NAD and NADP are consumed in foods, they are converted to nicotinamide in the gut and then absorbed".[4] The human trials accordingly test the precursors nicotinamide riboside and nicotinamide mononucleotide and measure NAD+ metabolites in blood or tissue.[1]
The cited oral precursor trials reported a rise in NAD+ metabolites
The largest nicotinamide riboside trial cited here enrolled 140 healthy overweight adults in an eight-week randomized, double-blind, placebo-controlled study of three NR amounts against placebo, funded by the ingredient's manufacturer; it reported that NR "dose-dependently and significantly increased whole blood NAD+" within two weeks, with the increases "maintained throughout the remainder of the study".[6] Martens and colleagues randomized 30 healthy middle-aged and older adults to a crossover of two six-week periods and reported that chronic NR "is well tolerated and effectively stimulates NAD+ metabolism".[7] For nicotinamide mononucleotide, Yi and colleagues randomized 80 healthy middle-aged adults to placebo or one of three daily oral NMN amounts for 60 days, in a trial fully funded by two NMN manufacturers that employ three of its authors, and reported blood NAD "statistically significantly increased among all NMN-treated groups at day 30 and day 60".[8] In 12 aged men, Elhassan and colleagues reported that NR "elevated the muscle NAD+ metabolome" and that "oral NR is available to aged human muscle", "without altering mitochondrial bioenergetics".[9]
| Trial | Design and participants | Population | What the authors reported |
|---|---|---|---|
| Conze 2019 | Randomized, double-blind, placebo-controlled, parallel; 140 enrolled | Healthy overweight adults | Whole blood NAD+ rose with each NR amount within two weeks and stayed elevated; no flushing; no difference in adverse events |
| Martens 2018 | Randomized, double-blind, placebo-controlled crossover; 30 randomized | Healthy middle-aged and older adults | NR well tolerated and stimulated NAD+ metabolism; 14 mild treatment-emergent adverse events in 7 of 30 participants |
| Yi 2023 | Randomized, multicenter, double-blind, placebo-controlled, parallel; 80 | Healthy middle-aged adults | Blood NAD rose in every NMN group; walking distance higher than placebo; biological age score unchanged against a rise on placebo |
| Elhassan 2019 | Randomized, double-blind, placebo-controlled crossover; 12 | Aged men | Muscle NAD+ metabolome elevated; inflammatory cytokines lower; mitochondrial bioenergetics unchanged |
| Dollerup 2018 | Randomized, double-blind, placebo-controlled, parallel; 40 | Men with obesity and insulin resistance | No improvement in insulin sensitivity, glucose metabolism, energy expenditure or body composition; no serious adverse events |
| Yoshino 2021 | Randomized, double-blind, placebo-controlled; 25 completed | Postmenopausal women with prediabetes who were overweight or obese | Insulin-stimulated glucose disposal and muscle insulin signaling increased after NMN and not after placebo |
| Brakedal 2022 (NADPARK) | Randomized, double-blinded phase I; 30 | Newly diagnosed, treatment-naive Parkinson disease population | Cerebral NAD rose, with variability, on MR spectroscopy; inflammatory cytokines fell; well tolerated |
Functional and metabolic outcomes were mixed or null across the precursor trials
The biochemical signal did not translate into a consistent clinical one. Dollerup and colleagues randomized 40 sedentary men with obesity and insulin resistance to twelve weeks of NR or placebo and reported that "Insulin sensitivity, endogenous glucose production, and glucose disposal and oxidation were not improved by NR supplementation", with no effect on energy expenditure, lipolysis or body composition.[10] Yoshino and colleagues, in a ten-week randomized placebo-controlled trial completed by 25 postmenopausal women with prediabetes who were overweight or obese, reported the opposite direction for NMN: insulin-stimulated glucose disposal and muscle insulin signaling "increased after NMN supplementation but did not change after placebo treatment".[11] A 2024 meta-analysis of eight randomized NMN trials in 342 middle-aged and older adults "indicated no significant benefit of NMN on fasting glucose, fasting insulin, glycated hemoglobin, homeostatic model assessment for insulin resistance and lipid profile".[12] In the Yi trial, six-minute walking distance increased more in every NMN group than on placebo, and a blood-based biological age score rose on placebo while staying unchanged on NMN, alongside no change in HOMA-IR.[8]
The NADPARK phase I trial enrolled 30 newly diagnosed, treatment-naive patients in a Parkinson disease population and reported that NR "led to a significant, but variable, increase in cerebral NAD levels" on phosphorus magnetic resonance spectroscopy, altered cerebral metabolism on PET "associated with mild clinical improvement" in those whose brain NAD rose, and lower inflammatory cytokines; the authors call for "further investigation in larger trials", and two of them hold a patent application on the use.[13] Across the whole literature, the 2026 systematic review concluded that "NAD⁺ augmentation shows clear biological activity, but clinical effectiveness for anti-aging or wellness outcomes remains inconclusive".[1]
Intravenous NAD+ has one pharmacokinetic pilot and no outcome trials
Compounded NAD+ given by injection or infusion is a different molecule on a different route from the oral precursors, and the controlled data are correspondingly thin. Grant and colleagues recruited eleven healthy men aged 30 to 55, randomized eight to a six-hour intravenous NAD+ infusion and three to saline, and reported that "no change in plasma (NAD+) or metabolites" was observed "until after 2 h", that NAD+ "is rapidly and completely removed from the plasma for at least the first 2 h", and that urinary excretion of NAD+ and methylnicotinamide rose by six hours; they describe it as the first data "on the fate of directly infused NAD+ in a human cohort".[2] Two of the authors are affiliated with an NAD+ research company and the wellness center that delivered the infusions.[2] The 2026 systematic review found no eligible outcome trial of intravenous or intramuscular NAD+ and called for larger randomized trials "particularly for parenteral approaches".[1] One randomized comparison is registered: NCT06919328, sponsored by the Nutraceuticals Research Institute with an industry collaborator, compares injectable nicotinamide riboside with NAD+ and a bacteriostatic water placebo in healthy adults, lists 70 estimated participants, and was recruiting at its last update posted on 9 April 2025, with no result posted as of 8 November 2026.[14]
What the trials and the fact sheet report on safety
Adverse event reporting in the precursor trials was consistent. Conze and colleagues recorded "no reports of flushing and no significant differences in adverse events between the NR and placebo-treated groups", and that NR "did not elevate low density lipoprotein cholesterol or dysregulate 1-carbon metabolism".[6] Martens and colleagues reported 14 treatment-emergent adverse events from 7 of 30 participants, all mild, with both side-effect withdrawals occurring in the placebo phase.[7] Dollerup and colleagues observed "No serious adverse events due to NR supplementation", and Yi and colleagues found "No safety issues, based on monitoring adverse events (AEs), laboratory and clinical measures".[8][10] For the parent vitamin, the Office of Dietary Supplements states that nicotinic acid "in supplemental amounts beyond nutritional needs can cause skin flushing", that "Nicotinamide does not produce skin flushing because of its slightly different chemical structure", that high intakes of nicotinic acid over months or years "can also be hepatotoxic", and that the Tolerable Upper Intake Level for supplemental niacin "does not apply to individuals who are receiving supplemental niacin under medical supervision".[4] The fact sheet makes no safety statement specific to injectable NAD+.[4] The intravenous pilot was designed to measure pharmacokinetics; its authors reported that no adverse events were observed during the six-hour infusion in either the NAD+ or the saline group, a finding from eight infused participants.[2]
FDA excluded NMN from the dietary supplement definition in 2022 and reversed that position in 2025
In letters dated 11 October 2022 and 4 November 2022 responding to new dietary ingredient notification 1259 for beta-nicotinamide mononucleotide, FDA's Center for Food Safety and Applied Nutrition determined that NMN "was not marketed as a dietary supplement, except unlawfully without an NDI notification, or as a food before FDA authorized it for investigation as a new drug", and concluded "that NMN is excluded from the dietary supplement definition under 21 U.S.C. § 321(ff)(3)(B)(ii) and may not be marketed as or in a dietary supplement."[15] The letters cite registered trials of an NMN drug candidate as the public investigations.[15]
The Office of Dietary Supplements fact sheet, last updated 18 November 2022, records the 2022 position: "FDA ruled in November 2022 that NMN may not be legally marketed as a dietary supplement because it has been authorized for investigation by FDA as a new drug."[4] FDA revisited that determination on 29 September 2025 in response to a citizen petition from the Natural Products Association and the Alliance for Natural Health USA. Having determined that "the first marketing of NMN as a dietary supplement in the United States preceded the authorization of NMN for investigation as a new drug", the agency concluded that "NMN is not excluded from the dietary supplement definition under section 201(ff)(3)(B)."[16]
Compounded NAD+ sits in category 1 of the FDA 503A bulk substances list
Section 503A(b)(1)(A) permits compounding with bulk drug substances that comply with "an applicable United States Pharmacopoeia or National Formulary monograph, if a monograph exists", or "if such a monograph does not exist, are drug substances that are components of drugs approved by the Secretary", or otherwise "appear on a list developed by the Secretary through regulations", provided they are made by a registered establishment and "are accompanied by valid certificates of analysis for each bulk drug substance".[17] The codified list at 21 CFR 216.23, as published on the eCFR for 5 November 2026, names six substances and none of them is NAD+.[18]
FDA's category PDF, updated 14 May 2026, places "Nicotinamide Adenine Dinucleotide (NAD)" and "Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH)" in category 1, "Bulk Drug Substances Under Evaluation", and places "Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate" in category 3, "Bulk Drug Substances Nominated Without Adequate Support".[19] FDA's bulk substances page, current as of the same date, states that the agency "will continue to evaluate sufficiently supported nominations for inclusion on the 503A bulks list in accordance with the process and criteria described in the FD&C Act".[20]
FDA's compounding questions and answers page states: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."[21] The same page says compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug".[21]
What the sources leave for a practice to document
The sources describe a precursor literature that reliably raises NAD+ metabolites with mixed downstream outcomes, and an injectable literature of one pharmacokinetic pilot and one recruiting trial.[1][2][14] The documents a practice would hold follow from the statute and the agency pages.[17][21]
- The pharmacy's certificate of analysis for the bulk NAD+, which section 503A(b)(1)(A)(iii) requires to accompany each bulk drug substance.
- The patient-specific prescription on which the 503A pharmacy compounded the preparation, since the exemption in section 503A applies only to a drug compounded for an identified individual patient.
- A note of which FDA category the salt the pharmacy sources sits in on the date of dispensing, because the category PDF changes.
- Patient counseling consistent with FDA's statement that compounded drugs are not FDA approved.
ExaVeyra's NAD+ reaches a practice through its licensed 503A pharmacy partner on a patient-specific prescription, with a certificate of analysis available for each lot; the catalog listing is at /products/small-molecules/nad-plus. Whether to use the compound, in which patients, by which route, and with what monitoring are decisions for the prescribing practitioner.[17][21]
This article summarizes published human studies and publicly available federal records for licensed practitioner education. It is not legal advice, medical advice, or regulatory guidance, and it does not establish that any particular product or practice is compliant. Confirm current federal and state obligations with qualified counsel.
Annotated References
Numbered in the order they are cited in the text. Each source is annotated with what it supports on this page; peer-reviewed articles are listed with journal, volume, issue and pages, and primary sources are regulations, agency documents, guidelines and position statements.
- 1.Peer-reviewedGallagher C, Emmanuel OO. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews. 2026;116:103057. https://pubmed.ncbi.nlm.nih.gov/41655607/Annotation: The 2010 to 2025 systematic review of 113 studies: consistent biochemical target engagement with oral NR and NMN, heterogeneous or null outcomes, and no eligible outcome trial of intravenous or intramuscular NAD+.
- 2.Peer-reviewedGrant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, Watson J. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Frontiers in Aging Neuroscience. 2019;11:257. https://pubmed.ncbi.nlm.nih.gov/31572171/Annotation: The controlled intravenous NAD+ pharmacokinetic pilot: eight men infused and three saline controls; no plasma change until after two hours; urinary NAD+ and methylnicotinamide at six hours; no adverse events observed during the infusion.
- 3.Peer-reviewedCovarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141. https://pubmed.ncbi.nlm.nih.gov/33353981/Annotation: NAD+ as a redox coenzyme and as a cofactor for sirtuins, CD38 and PARPs; the reported age-related decline; the authors' statement of what remains unknown about restoring NAD+ in humans.
- 4.Official sourceNIH Office of Dietary Supplements, Niacin: Fact Sheet for Health Professionals (updated 18 November 2022). Accessed 8 November 2026. https://ods.od.nih.gov/factsheets/Niacin-HealthProfessional/
- 5.Peer-reviewedCamacho-Pereira J, Tarragó MG, Chini CCS, Nin V, Escande C, Warner GM, Puranik AS, Schoon RA, Reid JM, Galina A, Chini EN. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metabolism. 2016;23(6):1127-1139. https://pubmed.ncbi.nlm.nih.gov/27304511/Annotation: The mouse finding that CD38 activity rises with age, is required for the age-related NAD decline, and is the main enzyme degrading NMN in vivo.
- 6.Peer-reviewedConze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Scientific Reports. 2019;9(1):9772. https://pubmed.ncbi.nlm.nih.gov/31278280/Annotation: The largest NR trial cited on this page: whole blood NAD+ rose with each amount within two weeks; no flushing; no adverse event difference against placebo; manufacturer funded.
- 7.Peer-reviewedMartens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9(1):1286. https://pubmed.ncbi.nlm.nih.gov/29599478/Annotation: The crossover trial in healthy middle-aged and older adults: NAD+ metabolism stimulated, tolerability, and the adverse event tally of 14 mild events in 7 of 30 participants.
- 8.Peer-reviewedYi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, Thasma S, Andhalkar N, Avhad G, Kumbhar V. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43. https://pubmed.ncbi.nlm.nih.gov/36482258/Annotation: The 60-day NMN trial: blood NAD rose in every NMN group; walking distance and a blood biological age score as the authors reported them; no safety issues; fully funded by two NMN manufacturers that employ three of its authors.
- 9.Peer-reviewedElhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, Cartwright DM, Oakey L, Burley CV, Jenkinson N, Wilson M, Lucas SJE, Akerman I, Seabright A, Lai YC, Tennant DA, Nightingale P, Wallis GA, Manolopoulos KN, Brenner C, Philp A, Lavery GG. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Reports. 2019;28(7):1717-1728.e6. https://pubmed.ncbi.nlm.nih.gov/31412242/Annotation: Oral NR reached aged human muscle and raised its NAD+ metabolome, lowered circulating inflammatory cytokines, and left mitochondrial bioenergetics unchanged.
- 10.Peer-reviewedDollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, Stødkilde-Jørgensen H, Møller N, Brenner C, Treebak JT, Jessen N. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. American Journal of Clinical Nutrition. 2018;108(2):343-353. https://pubmed.ncbi.nlm.nih.gov/29992272/Annotation: The null metabolic result: twelve weeks of NR did not improve insulin sensitivity, glucose metabolism, energy expenditure or body composition in men with obesity and insulin resistance; no serious adverse events.
- 11.Peer-reviewedYoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. https://pubmed.ncbi.nlm.nih.gov/33888596/Annotation: The positive metabolic result: insulin-stimulated glucose disposal and muscle insulin signaling increased after ten weeks of NMN in postmenopausal women with prediabetes who were overweight or obese.
- 12.Peer-reviewedChen F, Zhou D, Kong AP, Yim NT, Dai S, Chen YN, Hui LL. Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Current Diabetes Reports. 2024;25(1):4. https://pubmed.ncbi.nlm.nih.gov/39531138/Annotation: Eight randomized NMN trials pooled: no significant benefit on fasting glucose, fasting insulin, glycated hemoglobin, HOMA-IR or lipid profile.
- 13.Peer-reviewedBrakedal B, Dölle C, Riemer F, Ma Y, Nido GS, Skeie GO, Craven AR, Schwarzlmüller T, Brekke N, Diab J, Sverkeli L, Skjeie V, Varhaug K, Tysnes OB, Peng S, Haugarvoll K, Ziegler M, Grüner R, Eidelberg D, Tzoulis C. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metabolism. 2022;34(3):396-407.e6. https://pubmed.ncbi.nlm.nih.gov/35235774/Annotation: The phase I trial in a newly diagnosed Parkinson disease population: variable rise in cerebral NAD on MR spectroscopy, lower inflammatory cytokines, tolerability, and the authors' call for larger trials.
- 14.Official sourceClinicalTrials.gov, NCT06919328, Absorption and Tolerability of Injectable Administration of Niagen+, as Compared to NAD+ (Nutraceuticals Research Institute; recruiting, last update posted 9 April 2025). Accessed 8 November 2026. https://clinicaltrials.gov/study/NCT06919328
- 15.RegulatoryFDA Center for Food Safety and Applied Nutrition, letters to Inner Mongolia Kingdomway Pharmaceutical Limited regarding NDI 1259, beta-Nicotinamide Mononucleotide (11 October 2022 and 4 November 2022), docket FDA-2022-S-0023, document 0051 (regulations.gov). Accessed 8 November 2026. https://www.regulations.gov/document/FDA-2022-S-0023-0051
- 16.RegulatoryFDA Human Foods Program, response letter to the Natural Products Association and Alliance for Natural Health USA, citizen petition docket FDA-2023-P-0872, document 2754 (posted 29 September 2025), regulations.gov. Accessed 9 November 2026. https://www.regulations.gov/document/FDA-2023-P-0872-2754
- 17.Regulatory21 U.S.C. 353a, Pharmacy compounding (United States Code, 2024 edition, GPO). Accessed 8 November 2026. https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353a.htm
- 18.Regulatory21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A (eCFR, current through 5 November 2026). Accessed 8 November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23
- 19.RegulatoryFDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories 1, 2 and 3), PDF updated 14 May 2026. Accessed 8 November 2026. https://www.fda.gov/media/94155/download
- 20.RegulatoryFDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of 14 May 2026). Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- 21.RegulatoryFDA, Compounding and the FDA: Questions and Answers (content current as of 16 September 2025). Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Cite this page
ExaVeyra Sciences Editorial Team. NAD+ and Its Precursors: Human Trials. ExaVeyra Sciences; 9 November 2026. Available from: https://exaveyra.com/science/compounds/nad-plus-and-precursors-human-trials. Accessed [date accessed].